2[1]Rosenberg SA , Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes[J]. Annu Rev Immunol, 1986,4:681-709.
3[2]Oliver A, Canton L, Montanar M, et al. GM-CSF plus IL-2 administration associated with multiple autologous LAK reinfusion can induce a major cytogenetic response in early relapsed CML after autologous transplantation:a case report [J]. Bone Marrow Transplantation, 1998,21(1):65-69.
4[3]Ridolfi R, Flamini E, Riccobon A, et al. Adjuvant adoptive immunotherapy with tumor-infiltrating lymphocytes and modulated doses of IL-2 in 22 patients with melanoma, colorectal and renal cancer, after radical matastectomy, and in 12 advanced pa-tients[J]. Cancer Immunol Immunother, 1998,46(4):185-193.
5[4]Schmidt Wolf IG, Negrin RS,Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J]. J Exp Med, 1991,174(1):139-149.
6[5]Schmidt Wolf IG, Finke S,Trojaneck B,et al. Phase Ⅰ clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma[J]. Br J Cancer, 1999,81(6):1 009-1 016.
7童春容，实验血液学杂志，1996年，4卷，3期，314页
8Lu P H，J Immunol，1994年，153卷，4期，1687页
9Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol, 1994,153:1687-1696.
10Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3^+CD56^+ killer cells. Ann Hematol, 1997,74:51-56.
